Clinical Trial

JSKN003 Versus Trastuzumab Emtansine (T-DM1) for HER2-Positive, Advanced Breast Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study is designed to compare the safety and efficacy of JSKN003 versus T-DM1 in unrespectable locally advanced and/or metastatic HER2-positive breast cancer participants previously treated with trastuzumab and taxane.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-02-20.
Status change: Not Yet Recruiting → Recruiting 2025-03-19
Trial Details
NCT Number NCT06846437
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Unrespectable Locally Advanced and or Metastatic HER2 Positive Breast Cancer Participants
Enrollment 228 participants
Start Date 2025-02-18
Primary Completion 2026-10-13 (estimated)
Study Completion 2028-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-03-24